Compare HCA Health Inc (HCA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Illumina, Inc. — how do they compare? HCA Health Inc trades at $371.75 (market cap $82.17B), while Illumina, Inc. trades at $189.49 (market cap $27.94B). The key difference: HCA Health Inc is far larger — about 2.9× Illumina, Inc.'s market cap, and HCA Health Inc pays a 0.84% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| HCA | ILMN | |
|---|---|---|
Market Cap | $82.17B | $27.94B |
Sector | Health | Health |
52-Week High | $545.13 | $194.33 |
52-Week Low | $334.32 | $91.00 |
Enterprise Value | $131.08B | $29.33B |
Dividend Yield | 0.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.
The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
